<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757103</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0093</org_study_id>
    <nct_id>NCT04757103</nct_id>
  </id_info>
  <brief_title>Surgical Approach for Retrorectal Tumors Cohort</brief_title>
  <acronym>SART cohort</acronym>
  <official_title>Surgical Approach for Retro-rectal Tumors: a Retrospective Bicentric Cohort (SART Cohort)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study :&#xD;
&#xD;
      To evaluate postoperative outcomes of all surgical approach for retrorectal tumors.&#xD;
&#xD;
      Methods :&#xD;
&#xD;
      From 2005 to 2020, all consecutive patients who underwent surgery for a retrorectal tumor in&#xD;
      two referral tertiary center were prospectively collected.&#xD;
&#xD;
      Considering our exlusion criterias, data from XX patients were analyzed. The cohort was&#xD;
      separated into 2 groups according to tumor localization regarding the third sacral vertebra.&#xD;
&#xD;
      Short and longterm outcomes were compared between the two groups.&#xD;
&#xD;
      Primary outcome :&#xD;
&#xD;
      90 days postoperative morbidity rate&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retro-rectal tumors are a group of heterogeneous and rare lesions. The actual incidence has&#xD;
      been estimated to be approximately one case per 40,000 admissions. It is most often a benign&#xD;
      tumor that affects young women and the origin is congenital in 60% of cases. The most common&#xD;
      benign lesion is a tailgut cyst. Chordoma is the most common malignant lesion. They are&#xD;
      mostly asymptomatic or pauci-symptomatic. This is why their diagnosis is regularly&#xD;
      accidentaly after a morphological examination such as an abdominal ultrasound or a CT scan.&#xD;
      MRI is the gold standard for determining the structure of the lesion, its origin, its&#xD;
      topography, its extension in relation to adjacent organs, parameters that are essential to&#xD;
      define the type of surgery and its approach.&#xD;
&#xD;
      When a retro-rectal tumor is diagnosed, the standard treatment is surgical resection. A&#xD;
      biopsy is not helpful if there is no suspicion of a degenerate lesion. Usually, lesions&#xD;
      located under the third sacral vertebra (S3) are approached by dorsal transsacrococcygeal,&#xD;
      perineal or combined approach (abdominal and perineal approach) while those located above S3&#xD;
      the approach is abdominal (laparotomy or laparoscopy). As these lesions are, in the majority&#xD;
      of cases, benign, the functional impact of surgery is essential. Based on our experience in&#xD;
      minimally invasive surgery and in particular in retro-rectal tumors, laparoscopy has become&#xD;
      our first-line approach regardless of the location of the lesion compared to S3. Our&#xD;
      hypothesis is that the minimally invasive approach is reliable, safe and allows satisfactory&#xD;
      histological results to be obtained while limiting postoperative pain and functional&#xD;
      sequelae.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Actual">May 1, 2021</completion_date>
  <primary_completion_date type="Actual">January 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative morbidity rate</measure>
    <time_frame>90 days</time_frame>
    <description>Postoperative morbidity according to Clavien Dindo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>90 days</time_frame>
    <description>Mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation rate</measure>
    <time_frame>90 days</time_frame>
    <description>Any reoperation linked to surgical resection of the retrorectal tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of surgical resection</measure>
    <time_frame>90 days</time_frame>
    <description>Evaluation of surgical margins according to pathological examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion to open approach</measure>
    <time_frame>90 days</time_frame>
    <description>Conversion to laparotomy in case of mini-invasive approach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of functional outcomes</measure>
    <time_frame>90 days</time_frame>
    <description>Evaluation of fecal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of functional outcomes</measure>
    <time_frame>90 days</time_frame>
    <description>Evaluation urinary functions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcomes</measure>
    <time_frame>90 days</time_frame>
    <description>Evaluation of sexual functions</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">21</enrollment>
  <condition>Malignant Tumor</condition>
  <arm_group>
    <arm_group_label>Above S3</arm_group_label>
    <description>Lesion located above the third sacral vertebra</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Below S3</arm_group_label>
    <description>Lesion located below the third sacral vertebra</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Resection of the retrorectal tumor</intervention_name>
    <description>Surgical resection of the retrorectal mass</description>
    <arm_group_label>Above S3</arm_group_label>
    <arm_group_label>Below S3</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting a retrorectal tumor who underwent surgical excision&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patient presenting a retrorectal tumor&#xD;
&#xD;
          -  Surgical procedure between 01/01/2005 and 31/12/2020&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  age &lt; 18 years old&#xD;
&#xD;
          -  Patients presenting a rectal tumor&#xD;
&#xD;
          -  Patients presenting a rectal duplication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Bardol</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retrorectal tumor</keyword>
  <keyword>Tail gut cyst</keyword>
  <keyword>Benign tumor</keyword>
  <keyword>Mini-invasive approach</keyword>
  <keyword>Open approach</keyword>
  <keyword>Perineal approach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

